PROMIS NEUROSCIENCES INC (PMN)

CA74346M4065 - Common Stock

0.9418  -0.06 (-5.82%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PMN. PMN was compared to 572 industry peers in the Biotechnology industry. While PMN has a great health rating, there are worries on its profitability. PMN does not seem to be growing, but still is valued expensively.



2

1. Profitability

1.1 Basic Checks

In the past year PMN has reported negative net income.
In the past year PMN has reported a negative cash flow from operations.
In the past 5 years PMN always reported negative net income.
PMN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With an excellent Return On Assets value of -2.30%, PMN belongs to the best of the industry, outperforming 90.80% of the companies in the same industry.
The Return On Equity of PMN (-7.75%) is better than 90.97% of its industry peers.
Industry RankSector Rank
ROA -2.3%
ROE -7.75%
ROIC N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

PMN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PMN has been increased compared to 1 year ago.
Compared to 5 years ago, PMN has more shares outstanding
PMN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

PMN has an Altman-Z score of 0.14. This is a bad value and indicates that PMN is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of 0.14, PMN is doing good in the industry, outperforming 64.96% of the companies in the same industry.
There is no outstanding debt for PMN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.14
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 9.30 indicates that PMN has no problem at all paying its short term obligations.
PMN's Current ratio of 9.30 is fine compared to the rest of the industry. PMN outperforms 77.88% of its industry peers.
PMN has a Quick Ratio of 9.30. This indicates that PMN is financially healthy and has no problem in meeting its short term obligations.
PMN's Quick ratio of 9.30 is fine compared to the rest of the industry. PMN outperforms 78.05% of its industry peers.
Industry RankSector Rank
Current Ratio 9.3
Quick Ratio 9.3

0

3. Growth

3.1 Past

PMN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 89.84%, which is quite impressive.
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PMN is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.20% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.4%
EPS Next 2Y19.35%
EPS Next 3Y5.37%
EPS Next 5Y-7.2%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

PMN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PMN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.35%
EPS Next 3Y5.37%

0

5. Dividend

5.1 Amount

PMN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PROMIS NEUROSCIENCES INC

NASDAQ:PMN (1/14/2025, 8:00:01 PM)

0.9418

-0.06 (-5.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners30.81%
Inst Owner Change0%
Ins Owners4.31%
Ins Owner Change43.34%
Market Cap30.79M
Analysts85.71
Price Target7.99 (748.38%)
Short Float %0.95%
Short Ratio2.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)351.06%
Min EPS beat(2)8.06%
Max EPS beat(2)694.06%
EPS beat(4)3
Avg EPS beat(4)159.79%
Min EPS beat(4)-68.9%
Max EPS beat(4)694.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-10.48%
PT rev (3m)-10.48%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)81.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.23
P/tB 4.23
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.68
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.3%
ROE -7.75%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-137.72%
ROA(5y)-229.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.3
Quick Ratio 9.3
Altman-Z 0.14
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)6.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)89.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%321.05%
EPS Next Y93.4%
EPS Next 2Y19.35%
EPS Next 3Y5.37%
EPS Next 5Y-7.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-96.21%
EBIT Next 3Y-18.55%
EBIT Next 5Y33.13%
FCF growth 1Y-34.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.43%
OCF growth 3YN/A
OCF growth 5YN/A